Early interruption of clinical trials. Too good to be true?;Interrupción precoz de los ensayos clínicos. ¿Demasiado bueno para ser cierto?

Medicina Intensiva

Volumn 31, Issue 9, 2007, Pages 518-520

  Latour Perez J ^a   Cabello Lopez J B ^b,c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c Coordinación General de CASP ^*  (Spain)

Author keywords

Data monitoring committees; Ethics; Intermediate analyses; Randomized clinical trials; Statistical error

Indexed keywords

HEALTH CARE PERSONNEL; HUMAN; MEDICAL DECISION MAKING; MEDICAL ERROR; MEDICAL ETHICS; MEDICAL PRACTICE; PATIENT MONITORING; PRACTICE GUIDELINE; SHORT SURVEY;

EID: 36849043483     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(07)74859-3     Document Type: Article

References (15)

1. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet. 2005;365:1657-61.
2. Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials. 1989;10 Suppl 4:209S-21S.
3. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203-9.
4. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-91.
5. Damocles Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365:711-22.
6. Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ. 2006;332:1444-7.
7. Pocock SJ. When (not) to stop a clinical trial for benefit. JAMA. 2005;294:2228-30.
8. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341-52.
9. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338:347-54.
10. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-8.
11. Villar J, Kacmarek RM, Pérez-Méndez L, Aguirre-Jaime A. A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. Crit Care Med. 2006;34:1311-8.
12. Van del Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-67.
13. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodríguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47.
14. CASP-España. Herramientas para la lectura crítica. CASPEspaña. 13-6-2006. 4-7-2006.
15. Jaeschke R, Guyatt G, Barratt A, Walter S, Cook D, McAlister F, et al. User's guides to the medical literature. A manual for evidence-based clinical practice. Chicago: AMA Press; 2002.